publication

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

Koolen, B.B., Pengel, K.E., Wesseling, J., Vogel, W.V., Vrancken Peeters, M.J., Vincent, A.D., Gilhuijs, K.G.A., Rodenhuis, S, Rutgers, E.J., Valdes Olmos, R.A.

DOI: https://doi.org/10.1016/j.breast.2012.12.020

The Breast 22 (5), p. 691-697

Abstract